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Background:Myocardin is a cardiac- and smooth muscle-specific transcription factor.
Results:Myocardin is directly acetylated by p300.
Conclusion: Acetylation of myocardin is critical for myocardin to activate cardiac and smooth muscle target gene expression.
Significance: This study provides a molecular mechanism to explain how chromatin-remodeling enzymes participate in the
regulation of tissue-specific gene expression by directly modulating key transcription factors.
Myocardin belongs to the SAF-A/B, Acinus, PIAS (SAP)
domain family of transcription factors and is specifically
expressed in cardiac and smooth muscle. Myocardin functions
as a transcriptional coactivator of SRF and is sufficient and nec-
essary for smooth muscle gene expression. We have previously
found that myocardin induces the acetylation of nucleosomal
histones surrounding SRF-binding sites in the control regions of
cardiac and smooth muscle genes through recruiting chroma-
tin-modifying enzyme p300, yet no studies have determined
whether myocardin itself is similarly modified. In this study, we
show that myocardin is a direct target for p300-mediated acety-
lation. p300 acetylates lysine residues at the N terminus of the
myocardin protein. Interestingly, a direct interaction between
p300 and myocardin, which is mediated by the C terminus of
myocardin, is required for the acetylation event. Acetylation of
myocardin by p300 enhances the association of myocardin and
SRF as well as the formation of the myocardin-SRF-CArG
box ternary complex. Conversely, acetylation of myocardin
decreases the binding of histone deacetylase 5 (HDAC5) tomyo-
cardin. Acetylation of myocardin is required for myocardin to
activate smooth muscle genes. Our study demonstrates that
acetylationplays a key role inmodulatingmyocardin function in
controlling cardiac and smooth muscle gene expression.
Myocardin and myocardin-related transcription factors
(MRTFs)3 belong to a family of SAF-A/B, Acinus, PIAS (SAP)
domain transcription factors (1–3). Unlike many other tran-
scription factors, which bind to the conserved DNA sequences
on the regulatory regions of their target gene, myocardin and
MRTFs do not directly bind DNA. Instead, they form a ternary
complex with the serum-response factor (SRF) bound to the
DNAconsensus sequenceCC(A/T)6GG, knownas aCArGbox.
Such recruitment of myocardin and MRTFs brings the power-
ful transcription activation domain of myocardin and MRTFs
to SRF-dependent target genes with resulting transcriptional
activation (1, 4).WhereasMRTFs are broadly expressed inmul-
tiple tissue and cell types, myocardin expression is restricted to
muscle lineages (2, 5, 6). It has been demonstrated thatmyocar-
din transactivates the cardiac-specific gene atrial natriuretic
factor (ANF) and the smooth muscle-specific gene SM22, both
known targets for SRF (1, 7, 8). In addition, myocardin is a key
component of a molecular switch that regulates the ability of
SRF to mediate cellular proliferation and muscle cell differen-
tiation (4, 9). Genetic studies revealed that myocardin and
MRTFs play critical roles in a variety of biological processes,
including vascular smooth muscle development, aortic vessel
patterning, mammary myoepithelium formation, and others
(10–14).
Chromatin modification events, which include histone
acetylation, methylation, phosphorylation, and ubiquitination,
are central to the regulation of gene expression (15, 16). Acety-
lation introduces an acetyl functional group into the lysine res-
idues of a peptide, whereas deacetylation is the removal of the
acetyl group. Acetylation and deacetylation reactions are cata-
lyzed by enzymes with histone acetyltransferase (HAT) or his-
tone deacetylase (HDAC) activity, respectively. Acetylation and
deacetylation are most commonly found in the modification of
histones as part of gene regulation (17, 18). It is generally
believed that histone acetylation leads to the decondensation of
chromatin thus allowing for physical accessibility of the RNA
polymerase and transcriptional activation (17, 18). We have
previously found that the transcriptional activity of myocardin
is positively and negatively modulated by p300, a HAT, and
HDAC4 and HDAC5. p300 interacts with myocardin at its
C-terminal transactivation domain to enhance the transactivity
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of myocardin in activating cardiac and smooth muscle gene
expression (19).We have further demonstrated thatmyocardin
induces the acetylation of nucleosomal histones surrounding
SRF-binding sites in the control regions of smooth muscle
genes through recruitment of p300 (19). Interestingly, histone
is not the only substrate acetylated by p300. p300 has been
shown to acetylate transcription factors, including p53, MyoD,
and others (20–24), thereby changing the DNA-binding affin-
ity of transcription factors (25) or disrupting the ability of tran-
scription factors to recruit additional cofactors (26). Previously,
we proposed three putativemechanisms for p300 enhancement
of myocardin-mediated gene expression as follows: (i) p300
functions as a general transcriptional coactivator or adaptor,
(ii) p300 functions as a HAT to acetylate histones in nucleo-
somes at the regulatory regions of ANF and SM22 genes, and
(iii) p300 directly acetylates myocardin thereby enhancing its
transactivity (19).
In this study, we tested the hypothesis that p300 functions as
an acetyltransferase to directly acetylate myocardin.We report
here that indeed myocardin is a substrate for p300-dependent
acetylation modification. We also mapped acetylates sites to
the N-terminal regions of the myocardin protein. We found
that acetylation of myocardin enhances myocardin and SRF
interaction as well as the formation of the myocardin-SRF-
CArG box ternary complex. Our results indicate that acetyla-
tion of myocardin is critical for myocardin to activate smooth
muscle target gene expression.
EXPERIMENTAL PROCEDURES
Plasmids and Reporter Genes—Myocardin and HDAC
expression vectors have been described previously (2, 19, 27).
The p300 expression vectors were as described previously (19).
Myocardin mutants were generated through PCR-based
mutagenesis using the QuikChange kit from Stratagene. All
mutations were confirmed by DNA sequencing. The SM22-
luciferase reporter contained the 1434-bp promoter (2), and the
ANF-luciferase reporter contained the 638-bp promoter (2).
CMV-lacZ was included as an internal control for variations in
transfection efficiency.
Cell Culture andTransfectionAssays—Transfection ofCOS7
and 10T1/2 cells and luciferase assays were performed as
described previously (2, 19, 27). Unless otherwise indicated, 100
ng of reporter plasmid and 100 ng of each activator plasmid
were used. The total amount ofDNAperwell was kept constant
by adding the corresponding amount of expression vectorwith-
out a cDNA insert. All the transfection experiments were
repeated at least three times in duplicate.
GST-Protein Binding Assays—Plasmids encoding GST
fusion proteins were transformed into BL21-codon plus cells
(Stratagene). The cells were grown at 37 °C in 2 YT medium
to an optical density of 1.0. Isopropyl 1-thio--D-galactopyra-
noside (50 M) was then added to the culture to induce protein
expression. After shaking at room temperature for 4–6 h, the
cells were harvested, and the GST proteins were purified with
glutathione beads according to the procedure from GE
Healthcare.
Proteins translated in vitro were labeled with [35S]methio-
nine using aTNTT7-reticulocyte lysate system (Promega). Glu-
tathione beads conjugated with 1 g of protein were incubated
with 10 l of TNT product, at 4 °C for 2 h in 500 l of GST
binding buffer (20mMTris, pH 7.3, 150mMNaCl, 0.5%Nonidet
P-40, protease inhibitor mixture from Roche Applied Science,
and 1mMPMSF). The beadswerewashed three timeswithGST
binding buffer. Fifty microliters of SDS-loading buffer was then
added to the beads. After boiling, 20 l were loaded onto a
SDS-polyacrylamide gel.
Immunostaining and TUNEL Assays—Immunostaining was
performed as described previously (19). To determine the cel-
lular localization of myocardin and its mutants, COS7 cells
were transfected with FLAG-tagged myocardin constructs and
stained with anti-FLAG antibody (mouse monoclonal, M2,
Sigma). Myogenic conversion assays in 10T1/2 cells were per-
formed as described previously (19, 28), except that Lipo-
fectamine reagent (Invitrogen) was used for transfection.
Mouse anti-SM--actin monoclonal antibody (1A4, Sigma)
was used to monitor smooth muscle gene induction.
10T1/2 cells cultured in DMEM containing 10% FBS were
transfected with expression vectors encoding CMV-lacZ (con-
trol), myocardin, myocardin acetylation-deficient K4R mutant
(myocardin-K4R), andMyoD. 48 h later, cells were switched to
differentiation medium (DMEM containing 2% horse serum).
After an additional 48 h, the cells were collected and fixed and
then proceeded for TUNEL assay using the ApopTagPlus flu-
orescein in situ apoptosis detection kit (S7111, Chemicon)
according to the manufacturer’s manual.
Coimmunoprecipitation Assays—COS7 cells were tran-
siently transfected with plasmids encoding the epitope-tagged
myocardin, SRF, HDAC5, and p300 proteins as indicated in the
figure legends with FuGENE 6 reagent (Roche Applied Sci-
ence). 48 h after transfection, cells were harvested in lysis buffer
composed of phosphate-buffered saline (PBS) containing 0.5%
TritonX-100, 1mMEDTA, 1mMPMSF, and complete protease
inhibitors (Roche Applied Science). Following a brief sonica-
tion and removal of cellular debris by centrifugation, epitope-
tagged proteins were precipitated with antibodies as indicated
and protein A/G beads (Santa Cruz Biotechnology). The bound
proteins were washed five times with lysis buffer or washing
buffer with increasing salt concentrations (from 150, 350, and
550–750 mM NaCl), then resolved by SDS-PAGE, and trans-
ferred to polyvinylidene difluoride membranes (Bio-Rad).
Membranes were immunoblotted with antibodies as indicated,
and proteins were visualized with a chemiluminescence detec-
tion system (Santa Cruz Biotechnology).
In Vitro Acetylation Assay—In vitro acetylation assays were
performed as described previously (29). FLAG-tagged recom-
binant p300 protein (amino acids 1195–1810), which contains
the HAT domain and possesses HAT activity, and GST myo-
cardin or GST-myocardin mutant fusion proteins were
expressed in bacteria and affinity-purified to homogeneity. In
vitro acetylation assays were performed in 30 l of solution
containing 50mMHEPES, pH8.0, 10% glycerol, 1mMDTT, 1l
of [3H]acetyl-CoA (Amersham Biosciences), 1 mM PMSF, 10
mM sodium butyrate, 1 g of highly purified substrate proteins
or 2.5 g of GST fusion protein, and 100 ng of p300 and were
incubated at 30 °C for 1 h. The reaction was resolved by SDS-
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PAGE and dried and subjected to autoradiography at 70 °C
for 1–3 days.
RT-PCR—Total RNA was isolated with TRIzol reagent
(Invitrogen). After extraction andpurification, 1g of RNAwas
used as template for reverse transcription with random hex-
amer primers. PCR conditions and primer sequences are the
same as described previously (4, 19, 28). All PCR products span
the intron region of the genes.
Electrophoretic Mobility Shift Assay (EMSA)—EMSA was
carried out essentially as described previously (2, 19) with
minor modifications. The DNA-binding reactions (20 l) con-
tained 20mMTris-HCl, pH 7.5, 50 mMKCl, 5 mMMgCl2, 1 mM
DTT, 0.5 mM EDTA, 10% glycerol, 10 mM sodium butyrate, 0.5
mg/ml BSA, 100 ng poly(dI-dC), and proteins as indicated.
Reaction mixtures were preincubated at room temperature for
20 min before a 32P-labeled probe DNA (0.2 ng) was added and
further incubated at room temperature for 20 min. Each reac-
tion mixture was then loaded onto a native 4% polyacrylamide
gel (acrylamide:bisacrylamide, 50:1) containing 0.5 TBE and
electrophoresed in 0.25TBE at 180–220 V for 3 h. In the case
of supershift assays, the indicated monoclonal antibodies (200
ng) were added to reaction mixtures during preincubation.
RESULTS
Myocardin Is Acetylated by p300—To directly test whether
myocardin is a substrate for p300-mediated acetylation, we per-
formed in vitro acetylation assays, usingGST-myocardin fusion
proteins as a substrate. Indeed, the N-terminal region of myo-
cardin (amino acids 1–274) was efficiently acetylated by p300
(Fig. 1A). In contrast, no acetylation was detected in themiddle
and the C-terminal portions (amino acids 278–670 and amino
acids 670–935, respectively) of myocardin (Fig. 1A). As a neg-
ative control, GST protein was not acetylated. Notably, p300
also acetylates itself in these assays (Fig. 1A, upper bands), con-
sistent with previous reports (24).
Acetylation by acetyltransferase(s) occurs at lysine residues
(17, 24). The N terminus of myocardin (amino acids 1–274)
contains 26 lysine residues, which are potential acetylation
sites. A large proportion of those lysine residues are located
within the basic domain of myocardin protein, which also con-
tains its nuclear localization signal (Fig. 1B). To determine
which lysine residue(s) are accessible to acetylation, we system-
aticallymutated these lysine residues into arginines and assayed
their ability to be acetylated by p300 in vitro (Fig. 1C). Because
both arginine and lysine share similar chemical structure and
charge, the lysine to arginine mutation will minimize the effect
on other properties of the myocardin protein. Interestingly,
replacing individual lysines to arginines did not significantly
affect the acetylation state of myocardin (data not shown).
Although a definitivemolecular signature has yet to be estab-
lished for acetylation substrates, acetylation often occurs
within clusters of lysine residues (24). Two closely spaced clus-
ters of three lysines (amino acids 247–250 and 257–260)
located within the nuclear localization signal region of myocar-
din resemble the acetylation sites identified in other transcrip-
tion factors (24, 25, 30). To test their potential involvement, we
mutated these lysine clusters into arginine clusters. Surpris-
ingly, acetylation was not reduced but was further enhanced in
the mutant myocardin protein, indicating that those lysine res-
idues are unlikely the primary acetylation sites (Fig. 1C). Fur-
ther introducing mutation into additional lysines at position
253 and 255 reduced myocardin acetylation moderately (m2
andm3 in Fig. 1C).We continued this process and discovered a
dramatic reduction in acetylation when additional lysine resi-
dues (positions of 235 and 237) were alsomutated (m4,m5, and
m6 in Fig. 1C). Together, those analyses suggest that lysine res-
idues between amino acid 235 and 274 are critical for the acety-
lation of myocardin protein.
The above observations suggest that amino acids 235/237
and 253/255 could play a critical role in the acetylation of myo-
cardin.However, such a conclusion could be confounded by the
fact that simultaneous mutations were also introduced into
other lysine residues in those experiments. We therefore
decided to generatemyocardinmutants inwhich only two (Lys-
235/237 or Lys-253/255) or four lysines (Lys-235/237/253/255)
were mutated into arginines. As shown in Fig. 1D, myocardin
with two lysines being mutated (K2R) partially decreased its
acetylation (m7 and m8 in Fig. 1D). However, the myocardin
mutant with all four lysine residues mutated (thereafter called
K4Rmutant) was incapable of being acetylated (m9 in Fig. 1D).
These results indicate that multiple lysines in combination,
rather than any single lysine residue, are responsible for the
majority of myocardin acetylation by p300. These results are
consistent with prior observations reported in the acetylation
status of transcription factor YY1 and others (26, 31).
To determine whether myocardin is also acetylated in vivo,
we overexpressed FLAG-tagged myocardin or the myocardin
K4R mutant in COS7 cells together with a wild-type p300 or a
HAT-deficient p300 mutant (p300-DY) (19). Myocardin pro-
teins were immunoprecipitated with anti-FLAG antibodies,
and their acetylation status was determined by anti-acetyl-ly-
sine antibodies inWestern blots. Whereas myocardin is clearly
acetylated in the presence of wild-type p300 in vivo, the HAT-
deficient p300 mutant failed to acetylate myocardin (Fig. 1E).
Consistent with the in vitro result that the four lysine residues
are critical for myocardin acetylation, the myocardin K4R
mutant was not acetylated in vivo (data not shown). We have
previously reported that myocardin and p300 directly interact
in vitro and in vivo, and we have defined their interaction
domains at theC terminus of themyocardin protein (19). Inter-
estingly, myocardin(1–274), although sufficient to be acety-
lated in vitro (Fig. 1A), was incapable of being acetylated in vivo
(data not shown). These observations suggest that a physical
interaction between p300 andmyocardin, which ismediated by
myocardin C-terminal domains, is required for p300-mediated
myocardin acetylation in vivo.
Acetylation Is Required for the Transcriptional Synergy
between Myocardin and p300 to Activate Cardiac and Smooth
Muscle Reporter Genes—Having established that myocardin is
acetylated in vitro and in vivo by p300, we next investigated the
functional significance of this modification. We first examined
whether theHAT activity of p300 is required for the synergistic
transactivation of cardiac and smooth muscle gene expression
bymyocardin.Myocardin was cotransfected with the wild-type
or HAT-deficient p300 mutant into COS7 cells together with
SM22 or ANF luciferase reporter genes. As shown in Fig. 2A,
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increasing concentrations of wild-type p300 in the presence of
myocardin resulted in a synergistic and dose-dependent activa-
tion of ANF promoter luciferase reporter gene, consistent with
our prior report (19). However, cotransfection of a HAT-defi-
cient p300 mutant (p300-DY) failed to generate any synergy in
these assays (Fig. 2A), suggesting that p300 HAT activity is
required for the synergy between p300 and myocardin. Similar
observations were obtained on the SM22 luciferase reporter
gene (data not shown). Accordingly, the myocardin K2R and
K4Rmutants significantly decreased the ability ofmyocardin in
activating the ANF luciferase reporter gene. Most importantly,
such mutations abolished the synergy between myocardin and
p300 (Fig. 2B). Together, these results demonstrate that acety-
lation of myocardin is required for its synergistic cooperation
with p300 to activate the expression of cardiac and smooth
muscle genes.
Because these Lys-to-Argmutations occurwithin or near the
basic domain of myocardin, which also contains the nuclear
localization signal, we examined if those mutations affect the
nuclear localization of myocardin proteins. Transfection of the
wild-type or the Lys-to-Arg myocardin mutant constructs into
COS7 cells showed that the Lys-to-Arg mutations did not
change the nuclear location pattern ofmyocardin proteins (Fig.
2C). These observations suggest that themyocardin acetylation
did not affect the nuclear location of this protein, which further
implies that the loss of synergy betweenmyocardin acetylation-
FIGURE 1. Myocardin is acetylated by p300 in vitro and in vivo. A, in vitro acetylation assays. GST-myocardin fusion proteins or GST alone was incubated with
p300 in the presence of [3H]acetyl-CoA and resolved on SDS-PAGE. Only myocardin (myocd) (amino acids 1–274) was acetylated. p300 auto-acetylates itself
(upper bands). B, schematic diagram of myocardin protein with its signature domains marked. Partial amino acid sequences from the myocardin N-terminal
region with all 26 lysine residues were displayed. B, basic domain; Q, glutamine-rich domain; SAP, SAP domain; TAD, transactivation domain. C and D, in vitro
acetylation assays with GST-myocardin fusion protein (amino acids 1–274) and its derived Lys-to-Arg mutants or GST control. Acetylation results are summa-
rized in the lower panels. E, myocardin is acetylated by p300 in vivo. FLAG-tagged myocardin was transfected with either a wild-type (p300-WT) or a HAT-dead
mutant (p300-DY) of p300 into COS7 cells. Myocardin proteins were immunoprecipitated (IP) using an anti-FLAG antibody, and acetylated myocardin was
detected by acetyl-lysine-specific antibody (AcK). WB, Western blot.
Acetylation of Myocardin
38498 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287 • NUMBER 46 • NOVEMBER 9, 2012
deficient mutants and p300 did not result from the disruption
of myocardin nuclear localization in those mutants.
Acetylation of Myocardin Increases Its Affinity for SRF—To
determine whether acetylation of myocardin could modulate
its affinity for SRF, coimmunoprecipitation (Co-IP) assays were
performed with cell lysates containing equal amounts of HA-
tagged SRF, FLAG-taggedmyocardin, andMyc-tagged p300 or
the p300-DY mutant. After precipitation by anti-FLAG anti-
bodies, followed by washes with increasing salt concentrations
in washing buffer, the associated SRF was then detected by an
anti-HA antibody inWestern blot analyses. At low salt concen-
trations, the affinity of myocardin and SRF is 5–6-fold higher
when WT p300 was included (and therefore, myocardin was
predicted to be acetylated) than when p300-DY was included
(and therefore, myocardin acetylation was predicted to be
absent) (Fig. 3A). As salt concentration increases in thewashing
buffer (which correlates with increasing stringency for protein-
protein interaction), the association of SRF and nonacetylated
myocardin significantly diminished, whereas the association of
SRF and acetylatedmyocardin decreasedmuch slowly (Fig. 3A).
These data demonstrate that acetylated myocardin displays
higher affinity for SRF.
To further demonstrate that the observed difference in SRF-
myocardin association is due to myocardin acetylation, we
tested the ability of myocardin acetylation-deficient K4R
mutant to associate with SRF in similar Co-IP assays. After
precipitation by anti-FLAG antibodies, immunoprecipitates
were subjected to washing with increasing salt concentrations
in wash buffer. As expected, wild-type myocardin showed
much stronger binding affinity for SRF than the acetylation-
deficient myocardin K4R mutant (Fig. 3B). Together, these
results demonstrate that acetylation of myocardin enhances its
association with SRF.
Acetylation ofMyocardin Enhances the Formation of the SRF-
Myocardin-CArG Ternary Complex—Myocardin is a tran-
scriptional cofactor of SRF that does not bind to DNA by itself.
Instead, myocardin is recruited by SRF to the SRF-binding site,
the CArG box (1, 2, 7). To determine whether acetylation of
myocardin could modulate SRF binding to DNA as well as the
formation of the SRF-myocardin-CArG complex, EMSAs were
performed with nuclear extracts containing equal amounts of
SRF and p300 (or the p300-DY mutant) and an increasing
amount of myocardin. As shown in Fig. 4A, increasingmyocar-
din protein amounts result in the formation of a more stable
SRF-myocardin-CArG ternary complex in the presence of
wild-type (WT) p300 (Fig. 4A, lanes 2–5). In contrast, the SRF-
myocardin-CArG ternary complex formation was significantly
deceased in the presence of p300-DY (Fig. 4A, lanes 7–10). The
specificity of the ternary complex was demonstrated by anti-
body supershift (Fig. 4A, lanes 11 and 12). Together, these
results suggest that acetylation of the myocardin enhances the
formation of the SRF-myocardin-CArG ternary complex.
Noticeably, p300 appears to enhance the binding of SRF to the
FIGURE 2. Acetylation of myocardin is required for myocardin and p300 to synergistically activate cardiac reporter genes. A, COS7 cells were transiently
transfected with ANF-luciferase reporter and expression vectors encoding myocardin and increasing amounts of either wild-type (p300-WT) or mutant
(p300-DY) p300, and luciferase activity was measured. B, COS7 cells were transiently transfected with ANF-luciferase reporter and expression vectors encoding
p300 and either wild-type myocardin (myocardin-WT) or indicated myocardin mutants (myocd-m7, m8, and m9) and luciferase activity measured. The luciferase
activity was determined 48 h after transfection and was presented as fold of activation in which the control was assigned a value of 1. Data represent the
mean  S.D. from at least three independent experiments in duplicate. *, p  0.05. C, immunostaining of myocardin and its mutants. COS7 cells were transiently
transfected with expression vectors for FLAG-tagged myocardin, and its mutant constructs and the subcellular distribution of the proteins were determined by
immunostaining. DAPI staining marks the nuclei.
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CArG boxes as well, presumably due to an acetylation modifi-
cation of SRF (Fig. 4A).
To further confirm that the enhanced SRF-myocardin-CArG
complex formationwas indeed due to acetylation ofmyocardin,
we performed EMSAs using the acetylation-deficient myocar-
din mutants (both the K2R and the K4R mutants). When com-
parable levels of wild-type and mutant myocardin proteins
were used in these experiments, wild-type myocardin formed a
very stable SRF-myocardin-CArG ternary complex (Fig. 4B,
lanes 1–3), In contrast, theK2Rmutants significantly decreased
the formation of such ternary complexes (Fig. 4B, lanes 4–9).
Most importantly, the K4R mutant completely abolished the
formation of the SRF-myocardin-CArG ternary complexes.
Notably, acetylation-deficient myocardin K2R and K4R
mutants appear to have no (or very little) effect on the forma-
tion of the SRF-CArG complex (Fig. 4B, lanes 10–12).
Together, these data demonstrate that acetylationmodification
of myocardin is essential for its association with DNA-bound
SRF.
Acetylation ofMyocardin Decreases the Association of HDAC
andMyocardin—Myocardin transactivity is positively or nega-
tively modulated by HAT andHDAC, respectively. This is con-
FIGURE 3. Acetylation of myocardin enhances its association with SRF. A, COS7 cells were transiently transfected with FLAG-tagged myocardin, HA-tagged
SRF, and Myc-tagged p300 (p300-WT) or p300 mutants (p300-DY). FLAG-tagged myocardin (myocd) proteins were immunoprecipitated (IP) from cell lysates
using an anti-FLAG antibody. The precipitates were washed in washing buffers containing the indicated NaCl concentration. Associated HA-tagged SRF
proteins were then detected by an anti-HA antibody (left panels). Myocardin proteins were acetylated when cotransfected with wild-type p300 but not the
p300-DY mutant. Comparable amount of each proteins were used in the Co-IP experiments (right panels). WB, Western blot. B, co-IP experiments same as
described in A with the exception that both wild-type myocardin (myocd) and the myocardin K4R mutant were used.
FIGURE 4. Acetylation of myocardin is required for the formation of myocardin-SRF-CArG ternary complex. EMSAs were performed with a 32P-labeled
oligonucleotide probe for c-fos CArG and nuclear extracts containing the indicated proteins. A, FLAG-tagged myocardin and HA-tagged SRF were included in
the assay when either wild-type (WT) or mutant (DY) p300 proteins were also present. Note increased formation of myocardin-SRF-CArG ternary complex at the
presence of p300-WT. Anti-HA and anti-FLAG antibodies were used for supershift (lanes 11 and 12). B, same EMSAs as described in A with the exception that
both wild-type (WT) and acetylation-deficient K2R and K4R myocardin mutant proteins were used.
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sistent with the observation that myocardin can interact with
p300 andHDACproteins simultaneously (19). Previous studies
mapped the HDAC interacting domain to the N-terminal
region and p300 interacting domain to the C-terminal transac-
tivation domain of myocardin (19). Interestingly, we found that
myocardin acetylation by p300 occurs in its N-terminal region
(Fig. 1). We asked whether binding of p300 to myocardin and
subsequent acetylation modification could lead to de-associa-
tion of HDAC from myocardin. Coimmunoprecipitation
experiments were performed in which FLAG-tagged myocar-
din andMyc-taggedHDAC5were coexpressed in COS7 cells at
fixed levels, although HA-tagged p300 was expressed with
increasing levels. As shown in Fig. 5, the affinity of HDAC5 for
myocardin showed a decreasing trend when the level of p300
protein increased (Fig. 5, lanes 5–8). Consistent with the
hypothesis that myocardin acetylation status influences its
HDAC5 association, the acetylation-deficient myocardin K4R
mutant remains highly associated with HDAC5, even at the
presence of high p300 expression levels (Fig. 5, lanes 9–12).
Together, these data support the view that the acetylation sta-
tus of myocardin serves as a nodal point to determine whether
myocardin is associated with positive or negative transcrip-
tional regulators.
Acetylation of Myocardin Is Required to Activate Smooth
Muscle Gene Expression—Previously, myocardin has been
shown to sufficiently activate endogenous smooth muscle gene
expression when ectopically overexpressed in 10T1/2 fibro-
blasts (5, 28). To investigate the functional significance of myo-
cardin acetylation, we decided to test whether acetylation of
myocardin is required for the activation of smooth muscle
genes. As expected, SM22, SM--actin, and SM-MHC, markers
of smooth muscle cell but not cardiac -myosin heavy chain
(-MHC) or cardiac -actin, were induced by ectopic overex-
pression of wild-type myocardin (Fig. 6A), consistent with pre-
vious reports (19, 28). However, the induction of smooth mus-
cle markers was dramatically impaired in 10T1/2 cells
transfected with the acetylation-deficient myocardin K4R
mutant (Fig. 6A). As a control, MyoD potently induced the
expression of skeletal muscle -actin gene but not that of car-
diac or smooth muscle genes (Fig. 6A).
To further confirm the above observations, we transfected
10T1/2 fibroblasts with expression plasmid for wild-type myo-
cardin or the K4R mutant. The cells were then treated with
curcumin to inhibit the activity of p300. Curcumin is a natural
polyphenolic compound, and recent work has demonstrated
that curcumin could inhibit the p300-histone acetyltrans-
ferases and cardiomyocyte hypertrophy (32, 33). As shown in
Fig. 6B, myocardin, but not its K4Rmutant, was able to potently
activate the expression of smooth muscle genes SM22 and SM-
MHC (Fig. 6B, lanes 4). Curcumin treatment dramatically
inhibited myocardin-mediated activation of smooth muscle
genes but not that of controls (Fig. 6B, compare lanes 4 and 6).
These data suggest that acetylation modification of myocardin
is essential for the activation of its target smooth muscle genes.
We tested whether the acetylation of myocardin is involved
in apoptosis.We transfected 10T1/2 cells withmyocardinwild-
type or the K4Rmutant. As shown in Fig. 6C, overexpression of
myocardin, but not the myocardin-K4R mutant, induced the
expression of caspase-3, indicating an increase in apoptosis. As
a control, we showed thatMyoD also induced the expression of
caspase-3 (Fig. 6C). Such observation is further supported by
the results of TUNEL assays. Overexpression ofmyocardin, but
not themyocardin-K4Rmutant, resulted inmore TUNEL-pos-
itive cells when compared with controls (Fig. 6D). Together,
these data suggest that the acylation of myocardin also plays a
role in the regulation of apoptosis.
DISCUSSION
Regulation of gene expression plays a central role during the
cellular proliferation and differentiation processes (34, 35).
Dysregulation of gene expression is often associated with vari-
eties of pathophysiological conditions (34). It is known that
both sequence-specific DNA binding by transcription factors
and chromatin modification play an important role in the reg-
ulation of gene transcription (36). Previously, we have shown
thatmyocardin directly interacts with p300 andHDACs, which
positively or negativelymodulatesmyocardin transactivity (19).
In this study, we further explored the consequence of the myo-
cardin and p300 interaction.We found that myocardin is a tar-
get for acetylationmodification by p300. Acetylation ofmyocar-
din plays a central role inmodulatingmyocardin’s affinity for SRF
association as well as for the formation of the myocardin-SRF-
CArG ternary complex.Most importantly, we showed that acety-
lation of myocardin is essential for myocardin to activate cardiac
and smooth muscle gene expression. These studies provide a
molecular mechanism to explain how chromatin-remodeling
enzymes participate in the regulation of tissue-specific gene
expression by directly modulating key transcription factors.
Post-transcriptional modifications, including acetylation,
methylation, phosphorylation, and ubiquitination, are critical
to the function of modified proteins (15, 35). In the nucleus,
such modifications occur to both histone proteins and many
other nuclear proteins, including transcription factors. It is well
recognized that post-translational modification of histone pro-
teins is critical to chromatin structure and to the transcriptional
control of gene expression (15, 16). Recent studies have also
FIGURE 5. Acetylation of myocardin decreases its HDAC5 association.
COS7 cells were transiently transfected with FLAG-tagged myocardin (lanes 1
and 4 – 8) or the myocardin K4R mutant (lanes 9 –12), Myc-tagged HDAC5, and
increasing amounts of HA-tagged p300 as indicated. Myc-tagged HDAC5
proteins were immunoprecipitated (IP) from cell lysates using an anti-Myc
antibody. The precipitates were washed, and associated FLAG-tagged myo-
cardin (Myocd) (or myocardin K4R mutant) proteins were then detected by an
anti-FLAG antibody. Western blots (WB) demonstrate comparable amounts
of each proteins were used in the Co-IP experiments.
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documented that post-translational modification of transcrip-
tion factors contribute significantly to the activation of gene
expression (35). The first example of a non-histone protein tar-
get for HAT acetylation is p53, a well studied tumor suppressor
and transcription factor (24). It was shown that p300 acetylates
p53 at multiple lysine residues located at the C-terminal DNA
binding domain of the protein. As a consequence of acetylation,
p53 transactivity was enhanced. Conversely, HDAC1 deacety-
lates p53 in vitro and in vivo, thereby reversing the function of
p53 (24, 25). Another example of a p300 non-histone target for
acetylation is YinYang 1, orYY1, a transcription factor involved
in many biological processes. Intriguingly, YYI has been shown
to be either a transcriptional activator or repressor, depending
on the context (31). It is now known that YY1 can be acetylated
by p300 and deacetylated by HDACs (HDAC1, -2, and -3).
These acetylation and deacetylation modifications, together
with other post-translational modifications such as phosphor-
ylation, determine whether YY1 acts as a transcriptional acti-
vator or transcriptional repressor (31). In skeletal muscle,
MyoD, which belongs to the family of myogenic transcription
factors that function as “master” regulators to activate myo-
genic gene expression, was also identified as a target of p300
acetylation. Again, acetylation ofMyoD increased its transcrip-
tional activity, at least in part, by increasing its affinity for DNA
binding on the promoters and/or enhancers of genes induced
during muscle differentiation (22, 23). Our study demonstrates
myocardin as yet another key transcription factor target of
acetylation modification. Similar to our analysis of the nonac-
etylated form, acetylated myocardin does not bind to DNA
directly; instead, this post-translational modification promotes
formation of a more stable complex with SRF to potentiate its
binding to DNA and the formation of the myocardin-SRF-
CArG ternary complex. Interestingly, myocardin was shown to
repress cell proliferation and could function as a tumor sup-
pressor (37, 38). It will be important to determine whether
acetylation modification of myocardin contributes to its func-
tion in inhibiting cell proliferation.
In this study, we have defined four lysine residues inmyocar-
din that are primarily responsive to p300 acetylation. Myocar-
din belongs to the family of SAP-containing myocardin and
MRTFs (3, 39). We have examined the conservation of those
lysine residues amongmyocardin andMRTFprotein cross-spe-
cies. We found that Lys-235, Lys-237, and Lys-253 are highly
conserved among all myocardin family of transcription factors
in species fromXenopus to human. This is particular intriguing
given that myocardin was previously shown to activate cardiac
gene expression ectopically inXenopus embryos (40).We spec-
ulate that acetylationmodification is required formyocardin to
activate cardiac gene expression in this setting. However, Lys-
255 is conserved between myocardin and MRTF-A but not in
MRTF-B.4 It will be important to investigate whether MRTFs
4 D. Cao and D.-Z. Wang, unpublished data.
FIGURE 6. Myocardin acetylation-deficient mutant failed to activate smooth muscle gene expression. A,10T1/2 cells were transfected with expression
vectors encoding CMV-lacZ (control), myocardin (Myocd), myocardin acetylation-deficient K4R mutant (Myocd-K4R), and MyoD. Total RNAs were isolated, and
muscle gene expression was assayed by RT-PCR. GAPDH was measured as a loading control. B, 10T1/2 cells were transfected with expression vectors encoding
myocardin (Myocd) or myocardin acetylation-deficient K4R mutant (Myocd-K4R). Cells were treated with curcumin (or without treatment to serve as controls),
and total RNAs were isolated, and the expression of smooth muscle genes was assayed by RT-PCR. GAPDH was measured as a loading control. C, 10T1/2 cells
were transfected with the indicated expression vectors, and cell extracts were subjected to Western blots to document the expression of SM22 protein and
cleaved caspase-3. -Tubulin was used as a loading control (Cntl). D, 10T1/2 cells were transfected with indicated expression vectors, and apoptosis was
detected by TUNEL assays. DAPI marks the nuclei.
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are also subjected to acetylation modification and, if so, how
such modification alters their ability in activating target gene
expression.
Both p300 (HAT) and class II HDACs directly interact with
and regulate the transactivity of myocardin (19). Our data indi-
cate that binding of p300 to myocardin and subsequent acety-
lation led to its de-association fromHDAC5. It should be noted
that increasing p300 did not cause complete de-association of
HDAC5 from myocardin, suggesting that additional mecha-
nisms regulatingmyocardin activitymight exist. It will be inter-
esting for future studies to investigate whether the acetylation
and deacetylation of myocardin by p300 and HDACs is revers-
ible, and if so, how such dynamic switching between acetylated
and deacetylated states might affect the transcriptional prop-
erty of myocardin; more importantly, it will be crucial to deter-
mine whether such regulation is associated with cardiac and
smooth muscle gene expression during development and/or
pathological conditions.
It has previously been shown that HDAC5 was also able to
repress the transcriptional activity of MEF2C, a member of the
myocyte enhancer factor-2 (MEF2) family (41–45). Interest-
ingly, this repression can be released by calcium/calmodulin-
dependent protein kinase signaling, which apparently func-
tions to disruptMEF2-HDAC complexes and stimulate HDAC
nuclear export (46). This would suggest that HDAC-mediated
transcription repression is signal-dependent. Interestingly, we
have recently demonstrated that myocardin transactivity is
enhanced byTGF- and bonemorphogenetic protein signaling
pathways (27, 47), raising the possibility that those signaling
pathways could be involved in the activation of p300. It will be
intriguing to test whether calcium/calmodulin-dependent pro-
tein kinase signaling will release the repression of HDAC5 on
myocardin. In particular, it is important to determinewhether a
similar nuclear export mechanism is involved.
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